三月 2026
- Home
- Altasciences
三月 2026的Altasciences市场份额分析
contract research organization specialized in seamless, end-to-end, early phase drug development, we act to get your most promising compounds into and through early phase clinical trials.
Altasciences(包含公司地区分支机构)
查看更多网站流量和参与度信息- altasciences.com
Altasciences收入截至 三月 2026为 100M - 200M
Altasciences主要域名产生的收入
3 年中Altasciences主要域名的收入
Altasciences主要域名的收入
Altasciences热门域名的总访问量
了解Altasciences市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Altasciences热门域名的平均访问时长
分析Altasciences参与度指标。
过去 3 个月的平均访问时长
子公司明细
Altasciences热门域名的平均页面浏览量
了解Altasciences如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Altasciences 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Altasciences Co. hired Chris Perkin as CEO on Jul 1st '10.Chris joined Altasciences as CEO in 2010 and has played a central role in transforming the company from a clinical research organization, focused on testing of generic drugs, into a fully integrated early-phase contract research and contract drug manufacturing organization operating across nine North American locations.
二月 11, 2026阅读更多
新闻EcoVadis SAS partners with Altasciences Co..EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.
八月 20, 2025阅读更多
查看 Altasciences 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
